Dynavax COO exercises options, sells 114K shares

Dynavax Technologies Corp. insider activity: President & COO David F. Novack reported multiple equity transactions dated January 15, 2026.

Rhea-AI Filing Summary

Dynavax Technologies Corp. insider activity: President & COO David F. Novack reported multiple equity transactions dated January 15, 2026. He exercised stock options to acquire 20,000 common shares at $6.805 per share and 94,000 common shares at $10.47 per share. On the same date, he sold 114,000 common shares at a weighted average price of $15.64, leaving him with 63,344 common shares held directly after the transactions. The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 6, 2024, and notes that the sale price reflects trades executed between $15.585 and $15.665. Certain stock options involved in the exercises are described as fully vested.

Insider Trade Summary

Exercise and Sale: 114,000 shares ($663K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Novack David F

Role President & COO

Sold 114,000 shs ($1.78M)

Approx. gross sale proceeds $1.78M

Approx. exercise cost $1.12M

Approx. pre-tax spread $663K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	20,000	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	85,655	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	8,345	$0.00	$0.00
Exercise	Common Stock	20,000	$6.805	$136K
Exercise	Common Stock	94,000	$10.47	$984K
Sale	Common Stock	114,000	$15.64	$1.78M

Holdings After Transaction: Stock Option (Right to Buy) — 146,528 contracts (Direct); Common Stock — 63,344 shares (Direct)

Footnotes (4)

1. F1. The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 6, 2024.
2. F2. This transaction was executed in multiple trades at prices ranging from $15.585 to $15.665; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
3. F3. Fully vested.
4. F4. Not applicable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/20/2026 - 04:33 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Novack David F

(Last) (First) (Middle)

C/O DYNAVAX TECHNOLOGIES

2100 POWELL STREET, SUITE 720

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DYNAVAX TECHNOLOGIES CORP [ DVAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & COO

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		M(1)		20,000	A	$6.805	83,344	D
Common Stock	01/15/2026		M(1)		94,000	A	$10.47	177,344	D
Common Stock	01/15/2026		S(1)		114,000	D	$15.64(2)	63,344	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.805	01/15/2026		M(1)			20,000	(3)	12/15/2026	Common Stock	20,000	(4)	146,528	D
Stock Option (Right to Buy)	$10.47	01/15/2026		M(1)			85,655	(3)	02/21/2026	Common Stock	85,655	(4)	0	D
Stock Option (Right to Buy)	$10.47	01/15/2026		M(1)			8,345	(3)	02/21/2026	Common Stock	8,345	(4)	0	D

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 6, 2024.

2. This transaction was executed in multiple trades at prices ranging from $15.585 to $15.665; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.

3. Fully vested.

4. Not applicable.

Remarks:

	David F. Novack, by /s/ Trevor Dutcher, Attorney-in-Fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.